Long-Term Type 2 Diabetes Ups Pancreatic Cancer Mortality

This article originally appeared here.
Share this content:
Long-Term Type 2 Diabetes Ups Pancreatic Cancer Mortality
Long-Term Type 2 Diabetes Ups Pancreatic Cancer Mortality

(HealthDay News) – Among patients with pancreatic adenocarcinoma (PAC), those with pre-existing type 2 diabetes mellitus (T2DM) for longer than 5 years have an increased mortality risk, according to a study published online Aug. 1 in Cancer.

To assess the effect of varying durations of pre-existing T2DM on survival, Allen Hwang, MD, of the University of Pennsylvania in Philadelphia, and colleagues conducted a retrospective cohort study using data from The Health Improvement Network medical record database (2003 to 2010) for 3,147 patients with PAC. Of these, 745 had pre-existing T2DM and 2,402 did not.

In the primary analysis, the researchers found that there was no survival difference for those with and without pre-existing T2DM (hazard ratio, 1.02; P=0.620). In a secondary analysis, significantly increased mortality was seen for patients with T2DM of more than 5 years duration (hazard ratio, 1.16; P<0.05).

"In summary, we observed a significant increase in overall mortality in patients with a long-standing duration of T2DM (greater than 5 years)," the authors write. "The implications of these results are magnified by the growing prevalence of diabetes mellitus, the incidence of which has been increasing over the past 2 decades and is expected to nearly double over the next 25 years."

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs